{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T12:43:03Z","timestamp":1792586583305,"version":"4.5.0"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12948-8","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T10:20:34Z","timestamp":1792578034000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Novel approaches to target prostate cancer stem cells driving therapy resistance and cancer progression"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3595-7828","authenticated-orcid":false,"given":"Fatema S.","family":"Alatawi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,21]]},"reference":[{"issue":"4","key":"12948_CR1","first-page":"e70090","volume":"76","author":"H Sung","year":"2026","unstructured":"Sung H, Filho AM, Laversanne M, Ferlay J, Siegel RL, Soerjomataram I et al (2026) Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries. CA: A Cancer. J Clin 76(4):e70090","journal-title":"J Clin"},{"issue":"10437","key":"12948_CR2","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","volume":"403","author":"ND James","year":"2024","unstructured":"James ND, Tannock I, N\u2019Dow J, Feng F, Gillessen S, Ali SA et al (2024) The Lancet Commission on prostate cancer: planning for the surge in cases. Lancet 403(10437):1683\u20131722","journal-title":"Lancet"},{"key":"12948_CR3","doi-asserted-by":"crossref","unstructured":"Tilki D, van den Bergh RCN, Briers E, Chiu P, Eberli D, Epure A et al (2026) EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II\u20142026 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Eur Urol","DOI":"10.1016\/j.eururo.2026.04.014"},{"issue":"1","key":"12948_CR4","doi-asserted-by":"publisher","first-page":"5251","DOI":"10.1038\/s41467-019-13084-7","volume":"10","author":"LF van Dessel","year":"2019","unstructured":"van Dessel LF, van Riet J, Smits M, Zhu Y, Hamberg P, van der Heijden MS et al (2019) The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact. Nat Commun 10(1):5251","journal-title":"Nat Commun"},{"issue":"3","key":"12948_CR5","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nm.4045","volume":"22","author":"H Beltran","year":"2016","unstructured":"Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cyrta J et al (2016) Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med 22(3):298\u2013305","journal-title":"Nat Med"},{"issue":"10","key":"12948_CR6","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1002\/stem.2859","volume":"36","author":"S Skvortsov","year":"2018","unstructured":"Skvortsov S, Skvortsova I-I, Tang DG, Dubrovska A (2018) Concise Review: Prostate Cancer Stem Cells: Current Understanding. Stem Cells 36(10):1457\u20131474","journal-title":"Stem Cells"},{"issue":"5","key":"12948_CR7","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.stem.2012.03.009","volume":"10","author":"J Qin","year":"2012","unstructured":"Qin J, Liu X, Laffin B, Chen X, Choy G, Jeter CR et al (2012) The PSA(-\/lo) prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration. Cell Stem Cell 10(5):556\u2013569","journal-title":"Cell Stem Cell"},{"issue":"6320","key":"12948_CR8","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1126\/science.aah4307","volume":"355","author":"P Mu","year":"2017","unstructured":"Mu P, Zhang Z, Benelli M, Karthaus WR, Hoover E, Chen C-C et al (2017) SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science 355(6320):84\u201388","journal-title":"Science"},{"key":"12948_CR9","doi-asserted-by":"crossref","unstructured":"Jamroze A, Liu X, Tang DG (2024) Treatment-induced stemness and lineage plasticity in driving prostate cancer therapy resistance. Cancer Heterog Plast 1(1)","DOI":"10.47248\/chp2401010005"},{"issue":"6320","key":"12948_CR10","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1126\/science.aah4199","volume":"355","author":"SY Ku","year":"2017","unstructured":"Ku SY, Rosario S, Wang Y, Mu P, Seshadri M, Goodrich ZW et al (2017) Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science 355(6320):78\u201383","journal-title":"Science"},{"issue":"7","key":"12948_CR11","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1089\/ars.2013.5292","volume":"20","author":"P Gandellini","year":"2014","unstructured":"Gandellini P, Giannoni E, Casamichele A, Taddei ML, Callari M, Piovan C et al (2014) miR-205 hinders the malignant interplay between prostate cancer cells and associated fibroblasts. Antioxid Redox Signal 20(7):1045\u20131059","journal-title":"Antioxid Redox Signal"},{"issue":"7","key":"12948_CR12","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/nm0797-730","volume":"3","author":"D Bonnet","year":"1997","unstructured":"Bonnet D, Dick JE (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3(7):730\u2013737. https:\/\/doi.org\/10.1038\/nm0797-730","journal-title":"Nat Med"},{"issue":"7","key":"12948_CR13","doi-asserted-by":"publisher","first-page":"3983","DOI":"10.1073\/pnas.0530291100","volume":"100","author":"M Al-Hajj","year":"2003","unstructured":"Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100(7):3983\u20133988. https:\/\/doi.org\/10.1073\/pnas.0530291100","journal-title":"Proc Natl Acad Sci USA"},{"key":"12948_CR14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1146\/annurev-pathol-012615-044438","volume":"11","author":"D Nassar","year":"2016","unstructured":"Nassar D, Blanpain C (2016) Cancer Stem Cells: Basic Concepts and Therapeutic Implications. Annu Rev Pathol 11:47\u201376","journal-title":"Annu Rev Pathol"},{"issue":"5","key":"12948_CR15","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/s41568-021-00332-6","volume":"21","author":"AW Lambert","year":"2021","unstructured":"Lambert AW, Weinberg RA (2021) Linking EMT programmes to normal and neoplastic epithelial stem cells. Nat Rev Cancer 21(5):325\u2013338","journal-title":"Nat Rev Cancer"},{"key":"12948_CR16","doi-asserted-by":"publisher","first-page":"1617200","DOI":"10.3389\/fcell.2025.1617200","volume":"13","author":"H Chen","year":"2025","unstructured":"Chen H, Li Z, Yue Y, Zhu X, Wang J, Chen Y et al (2025) CAF-mediated regulation of prostate cancer stem cell stemness via the Wnt\/\u03b2-catenin and SDF-1\/CXCR4 pathways in castration-resistant prostate cancer. Front Cell Dev Biology 13:1617200. https:\/\/doi.org\/10.3389\/fcell.2025.1617200","journal-title":"Front Cell Dev Biology"},{"issue":"4","key":"12948_CR17","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1172\/JCI43414","volume":"121","author":"Y Shiozawa","year":"2011","unstructured":"Shiozawa Y, Pedersen EA, Havens AM, Jung Y, Mishra A, Joseph J et al (2011) Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest 121(4):1298\u20131312. https:\/\/doi.org\/10.1172\/JCI43414","journal-title":"J Clin Invest"},{"issue":"7","key":"12948_CR18","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1007\/s12094-023-03093-w","volume":"25","author":"K Wu","year":"2023","unstructured":"Wu K, Wu M, Yang H, Diao R, Zeng H (2023) Hypoxia promotes conversion to a stem cell phenotype in prostate cancer cells by activating HIF-1\u03b1\/Notch1 signaling pathway. Clin Transl Oncol 25(7):2138\u20132152","journal-title":"Clin Transl Oncol"},{"issue":"6","key":"12948_CR19","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.3390\/cells9061441","volume":"9","author":"BG S\u00e1nchez","year":"2020","unstructured":"S\u00e1nchez BG, Bort A, Vara-Ciruelos D, D\u00edaz-Laviada I (2020) Androgen Deprivation Induces Reprogramming of Prostate Cancer Cells to Stem-Like Cells. Cells 9(6):1441","journal-title":"Cells"},{"issue":"12","key":"12948_CR20","doi-asserted-by":"publisher","first-page":"3530","DOI":"10.1016\/j.celrep.2018.11.086","volume":"25","author":"GH Henry","year":"2018","unstructured":"Henry GH, Malewska A, Joseph DB, Malladi VS, Lee J, Torrealba J et al (2018) A Cellular Anatomy of the Normal Adult Human Prostate and Prostatic Urethra. Cell Rep 25(12):3530\u201342e5","journal-title":"Cell Rep"},{"key":"12948_CR21","doi-asserted-by":"publisher","first-page":"e59465","DOI":"10.7554\/eLife.59465","volume":"9","author":"L Crowley","year":"2020","unstructured":"Crowley L, Cambuli F, Aparicio L, Shibata M, Robinson BD, Xuan S et al (2020) A single-cell atlas of the mouse and human prostate reveals heterogeneity and conservation of epithelial progenitors. eLife 9:e59465","journal-title":"eLife"},{"issue":"4","key":"12948_CR22","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41585-021-00561-2","volume":"19","author":"M Baures","year":"2022","unstructured":"Baures M, Dariane C, Tika E, Puig Lombardi E, Barry Delongchamps N, Blanpain C et al (2022) Prostate luminal progenitor cells: from mouse to human, from health to disease. Nat Reviews Urol 19(4):201\u2013218","journal-title":"Nat Reviews Urol"},{"issue":"2","key":"12948_CR23","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nprot.2016.006","volume":"11","author":"J Drost","year":"2016","unstructured":"Drost J, Karthaus WR, Gao D, Driehuis E, Sawyers CL, Chen Y et al (2016) Organoid culture systems for prostate epithelial and cancer tissue. Nat Protoc 11(2):347\u2013358","journal-title":"Nat Protoc"},{"issue":"11","key":"12948_CR24","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1002\/pros.24020","volume":"80","author":"DB Joseph","year":"2020","unstructured":"Joseph DB, Henry GH, Malewska A, Iqbal NS, Ruetten HM, Turco AE et al (2020) Urethral luminal epithelia are castration-insensitive cells of the proximal prostate. Prostate 80(11):872\u2013884","journal-title":"Prostate"},{"issue":"23","key":"12948_CR25","doi-asserted-by":"publisher","first-page":"10946","DOI":"10.1158\/0008-5472.CAN-05-2018","volume":"65","author":"AT Collins","year":"2005","unstructured":"Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65(23):10946\u201310951","journal-title":"Cancer Res"},{"issue":"12","key":"12948_CR26","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1038\/sj.onc.1209327","volume":"25","author":"L Patrawala","year":"2006","unstructured":"Patrawala L, Calhoun T, Schneider-Broussard R, Li H, Bhatia B, Tang S et al (2006) Highly purified CD44\u2009+\u2009prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 25(12):1696\u20131708. https:\/\/doi.org\/10.1038\/sj.onc.1209327","journal-title":"Oncogene"},{"issue":"12","key":"12948_CR27","doi-asserted-by":"publisher","first-page":"5163","DOI":"10.1158\/0008-5472.CAN-09-3806","volume":"70","author":"C van den Hoogen","year":"2010","unstructured":"van den Hoogen C, van der Horst G, Cheung H, Buijs JT, Lippitt JM, Guzman-Ramirez N et al (2010) High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer. Cancer Res 70(12):5163\u20135173. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-3806","journal-title":"Cancer Res"},{"issue":"6","key":"12948_CR28","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.stem.2010.11.013","volume":"7","author":"RU Lukacs","year":"2010","unstructured":"Lukacs RU, Memarzadeh S, Wu H, Witte ON (2010) Bmi-1 Is a Crucial Regulator of Prostate Stem Cell Self-Renewal and Malignant Transformation. Cell Stem Cell 7(6):682\u2013693","journal-title":"Cell Stem Cell"},{"key":"12948_CR29","doi-asserted-by":"crossref","unstructured":"Cornford P, van den Bergh RCN, Briers E, Chiu P, Eberli D, Epure A et al (2026) EAU\u2013EANM\u2013ESTRO\u2013ESUR\u2013ISUP\u2013SIOG Guidelines on Prostate Cancer\u20142026 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol","DOI":"10.1016\/j.eururo.2026.04.013"},{"issue":"12","key":"12948_CR30","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","volume":"386","author":"MR Smith","year":"2022","unstructured":"Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED et al (2022) Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. N Engl J Med 386(12):1132\u20131142","journal-title":"N Engl J Med"},{"issue":"10336","key":"12948_CR31","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","volume":"399","author":"K Fizazi","year":"2022","unstructured":"Fizazi K, Foulon S, Carles J, Roubaud G, McDermott R, Fl\u00e9chon A et al (2022) Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design. Lancet 399(10336):1695\u20131707","journal-title":"Lancet"},{"key":"12948_CR32","unstructured":"U.S. Food and Drug Administration. FDA approves capivasertib with abiraterone and prednisone for PTEN-deficient androgen pathway modulation-na\u00efve or -sensitive prostate cancer. 12 June 2026 [accessed 4 October 2026]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-capivasertib-abiraterone-and-prednisone-pten-deficient-androgen-pathway-modulation"},{"issue":"22","key":"12948_CR33","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"J de Bono","year":"2020","unstructured":"de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S et al (2020) Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med 382(22):2091\u20132102","journal-title":"N Engl J Med"},{"issue":"26","key":"12948_CR34","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1056\/NEJMoa1911206","volume":"381","author":"R de Wit","year":"2019","unstructured":"de Wit R, de Bono J, Sternberg CN, Fizazi K, Tombal B, W\u00fclfing C et al (2019) Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. N Engl J Med 381(26):2506\u20132518","journal-title":"N Engl J Med"},{"issue":"10323","key":"12948_CR35","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","volume":"399","author":"G Attard","year":"2022","unstructured":"Attard G, Murphy L, Clarke NW, Cross W, Jones RJ, Parker CC et al (2022) Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet 399(10323):447\u2013460","journal-title":"Lancet"},{"issue":"5","key":"12948_CR36","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1159\/000363186","volume":"87","author":"R-J Kim","year":"2014","unstructured":"Kim R-J, Bae E, Hong YK, Hong JY, Kim NK, Ahn HJ et al (2014) PTEN Loss-Mediated Akt Activation Increases the Properties of Cancer Stem-Like Cell Populations in Prostate Cancer. Oncology 87(5):270\u2013279","journal-title":"Oncology"},{"issue":"5","key":"12948_CR37","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.ccr.2011.04.008","volume":"19","author":"BS Carver","year":"2011","unstructured":"Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S et al (2011) Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer. Cancer Cell 19(5):575\u2013586","journal-title":"Cancer Cell"},{"issue":"10295","key":"12948_CR38","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0140-6736(21)00580-8","volume":"398","author":"C Sweeney","year":"2021","unstructured":"Sweeney C, Bracarda S, Sternberg CN, Chi KN, Olmos D, Sandhu S et al (2021) Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. Lancet 398(10295):131\u2013142","journal-title":"Lancet"},{"issue":"6","key":"12948_CR39","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.eururo.2024.12.015","volume":"87","author":"JS de Bono","year":"2025","unstructured":"de Bono JS, He M, Shi Z, Nowicka M, Bracarda S, Sternberg CN et al (2025) Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 Trial. Eur Urol 87(6):672\u2013682","journal-title":"Eur Urol"},{"issue":"1","key":"12948_CR40","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.annonc.2025.10.004","volume":"37","author":"K Fizazi","year":"2026","unstructured":"Fizazi K, Clarke NW, De Santis M, Uemura H, Fay AP et al (2026) Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study\u2606. Ann Oncol 37(1):53\u201368","journal-title":"Ann Oncol"},{"issue":"4","key":"12948_CR41","doi-asserted-by":"publisher","first-page":"e61716","DOI":"10.1371\/journal.pone.0061716","volume":"8","author":"AP Rybak","year":"2013","unstructured":"Rybak AP, Ingram AJ, Tang D (2013) Propagation of human prostate cancer stem-like cells occurs through EGFR-mediated ERK activation. PLoS ONE 8(4):e61716","journal-title":"PLoS ONE"},{"issue":"7","key":"12948_CR42","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1158\/0008-5472.CAN-11-3132","volume":"72","author":"DJ Mulholland","year":"2012","unstructured":"Mulholland DJ, Kobayashi N, Ruscetti M, Zhi A, Tran LM, Huang J et al (2012) Pten Loss and RAS\/MAPK Activation Cooperate to Promote EMT and Metastasis Initiated from Prostate Cancer Stem\/Progenitor Cells. Cancer Res 72(7):1878\u20131889","journal-title":"Cancer Res"},{"issue":"9","key":"12948_CR43","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1172\/JCI34764","volume":"118","author":"CW Kinkade","year":"2008","unstructured":"Kinkade CW, Castillo-Martin M, Puzio-Kuter A, Yan J, Foster TH, Gao H et al (2008) Targeting AKT\/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest 118(9):3051\u20133064. https:\/\/doi.org\/10.1172\/JCI34764","journal-title":"J Clin Invest"},{"issue":"3","key":"12948_CR44","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.urology.2009.05.016","volume":"74","author":"C Nabhan","year":"2009","unstructured":"Nabhan C, Lestingi TM, Galvez A, Tolzien K, Kelby SK, Tsarwhas D et al (2009) Erlotinib Has Moderate Single-agent Activity in Chemotherapy-na\u00efve Castration-resistant Prostate Cancer: Final Results of a Phase II Trial. Urology 74(3):665\u2013671","journal-title":"Urology"},{"issue":"5","key":"12948_CR45","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1080\/15384047.2020.1727702","volume":"21","author":"A Rossini","year":"2020","unstructured":"Rossini A, Giussani M, Ripamonti F, Aiello P, Regondi V, Balsari A et al (2020) Combined targeting of EGFR and HER2 against prostate cancer stem cells. Cancer Biol Ther 21(5):463\u2013475","journal-title":"Cancer Biol Ther"},{"issue":"1","key":"12948_CR46","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41392-023-01559-5","volume":"8","author":"J Jing","year":"2023","unstructured":"Jing J, Wu Z, Wang J, Luo G, Lin H, Fan Y et al (2023) Hedgehog signaling in tissue homeostasis, cancers, and targeted therapies. Signal Transduct Target Ther 8(1):315","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"12948_CR47","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1007\/s00280-016-3191-7","volume":"78","author":"BL Maughan","year":"2016","unstructured":"Maughan BL, Suzman DL, Luber B, Wang H, Glavaris S, Hughes R et al (2016) Pharmacodynamic study of the oral hedgehog pathway inhibitor, vismodegib, in patients with metastatic castration-resistant prostate cancer. Cancer Chemother Pharmacol 78(6):1297\u20131304","journal-title":"Cancer Chemother Pharmacol"},{"issue":"61","key":"12948_CR48","doi-asserted-by":"publisher","first-page":"104182","DOI":"10.18632\/oncotarget.22115","volume":"8","author":"AE Ross","year":"2017","unstructured":"Ross AE, Hughes RM, Glavaris S, Ghabili K, He P, Anders NM et al (2017) Pharmacodynamic and pharmacokinetic neoadjuvant study of hedgehog pathway inhibitor Sonidegib (LDE-225) in men with high-risk localized prostate cancer undergoing prostatectomy. Oncotarget 8(61):104182\u2013104192","journal-title":"Oncotarget"},{"issue":"51","key":"12948_CR49","doi-asserted-by":"publisher","first-page":"84286","DOI":"10.18632\/oncotarget.12483","volume":"7","author":"A Gonnissen","year":"2016","unstructured":"Gonnissen A, Isebaert S, McKee CM, Dok R, Haustermans K, Muschel RJ (2016) The hedgehog inhibitor GANT61 sensitizes prostate cancer cells to ionizing radiation both in vitro and in vivo. Oncotarget 7(51):84286\u201384298","journal-title":"Oncotarget"},{"issue":"878","key":"12948_CR50","doi-asserted-by":"publisher","first-page":"eadi5174","DOI":"10.1126\/scisignal.adi5174","volume":"18","author":"Q Zhang","year":"2025","unstructured":"Zhang Q, Peng J, Zhang Y, Liu J, He D, Zhao Y et al (2025) The kinase PLK1 promotes Hedgehog signaling\u2013dependent resistance to the antiandrogen enzalutamide in metastatic prostate cancer. Sci Signal 18(878):eadi5174","journal-title":"Sci Signal"},{"issue":"12","key":"12948_CR51","doi-asserted-by":"publisher","first-page":"a007880","DOI":"10.1101\/cshperspect.a007880","volume":"4","author":"BT MacDonald","year":"2012","unstructured":"MacDonald BT, He X, Frizzled (2012) LRP5\/6 receptors for Wnt\/\u03b2-catenin signaling. Cold Spring Harb Perspect Biol 4(12):a007880. https:\/\/doi.org\/10.1101\/cshperspect.a007880","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"9","key":"12948_CR52","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1002\/mc.23565","volume":"62","author":"IM Atawia","year":"2023","unstructured":"Atawia IM, Kushwaha PP, Verma S, Lin S, Shankar E, Abdel-Gawad O et al (2023) Inhibition of Wnt\/\u03b2-catenin pathway overcomes therapeutic resistance to abiraterone in castration-resistant prostate cancer. Mol Carcinog 62(9):1312\u20131324","journal-title":"Mol Carcinog"},{"issue":"6","key":"12948_CR53","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/cr.2009.43","volume":"19","author":"I Bisson","year":"2009","unstructured":"Bisson I, Prowse DM (2009) WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics. Cell Res 19(6):683\u2013697","journal-title":"Cell Res"},{"issue":"1","key":"12948_CR54","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.bbrc.2020.04.112","volume":"527","author":"F Wang","year":"2020","unstructured":"Wang F, Zhu Y, Wang F, Wang Y, Dong B-j, Wang N et al (2020) Wnt\/\u03b2-catenin signaling contributes to prostate cancer heterogeneity through reciprocal suppression of H3K27 trimethylation. Biochem Biophys Res Commun 527(1):242\u2013249","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"12948_CR55","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41416-021-01389-8","volume":"125","author":"J Rodon","year":"2021","unstructured":"Rodon J, Argil\u00e9s G, Connolly RM, Vaishampayan U, de Jonge M, Garralda E et al (2021) Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours. Br J Cancer 125(1):28\u201337","journal-title":"Br J Cancer"},{"key":"12948_CR56","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1146\/annurev-biochem-013118-111829","volume":"88","author":"S Ma","year":"2019","unstructured":"Ma S, Meng Z, Chen R, Guan KL (2019) The Hippo Pathway: Biology and Pathophysiology. Annu Rev Biochem 88:577\u2013604","journal-title":"Annu Rev Biochem"},{"issue":"1","key":"12948_CR57","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.canlet.2016.05.010","volume":"378","author":"N Liu","year":"2016","unstructured":"Liu N, Mei L, Fan X, Tang C, Ji X, Hu X et al (2016) Phosphodiesterase 5\/protein kinase G signal governs stemness of prostate cancer stem cells through Hippo pathway. Cancer Lett 378(1):38\u201350","journal-title":"Cancer Lett"},{"issue":"20","key":"12948_CR58","doi-asserted-by":"publisher","first-page":"4014","DOI":"10.1038\/s41388-020-1272-x","volume":"39","author":"Y Goto","year":"2020","unstructured":"Goto Y, Ando T, Izumi H, Feng X, Arang N, Gilardi M et al (2020) Muscarinic receptors promote castration-resistant growth of prostate cancer through a FAK\u2013YAP signaling axis. Oncogene 39(20):4014\u20134027","journal-title":"Oncogene"},{"issue":"4","key":"12948_CR59","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/pros.23476","volume":"78","author":"HM Lin","year":"2018","unstructured":"Lin HM, Lee BY, Castillo L, Spielman C, Grogan J, Yeung NK et al (2018) Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer. Prostate 78(4):308\u2013317","journal-title":"Prostate"},{"issue":"12","key":"12948_CR60","doi-asserted-by":"publisher","first-page":"4281","DOI":"10.1038\/s41591-025-04029-3","volume":"31","author":"TA Yap","year":"2025","unstructured":"Yap TA, Kwiatkowski DJ, Dagogo-Jack I, Offin M, Zauderer MG, Kratzke R et al (2025) YAP\/TEAD inhibitor VT3989 in solid tumors: a phase 1\/2 trial. Nat Med 31(12):4281\u20134290","journal-title":"Nat Med"},{"issue":"4","key":"12948_CR61","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1158\/0008-5472.CAN-13-0594","volume":"74","author":"A Schroeder","year":"2014","unstructured":"Schroeder A, Herrmann A, Cherryholmes G, Kowolik C, Buettner R, Pal S et al (2014) Loss of Androgen Receptor Expression Promotes a Stem-like Cell Phenotype in Prostate Cancer through STAT3 Signaling. Cancer Res 74(4):1227\u20131237","journal-title":"Cancer Res"},{"issue":"2","key":"12948_CR62","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1002\/pros.24632","volume":"84","author":"L Wang","year":"2024","unstructured":"Wang L, Lyu C, Stadlbauer B, Buchner A, N\u00f6\u00dfner E, Pohla H (2024) Berbamine targets cancer stem cells and reverses cabazitaxel resistance via inhibiting IGF2BP1 and p-STAT3 in prostate cancer. Prostate 84(2):131\u2013147","journal-title":"Prostate"},{"issue":"8","key":"12948_CR63","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1002\/pros.24125","volume":"81","author":"MH Thulin","year":"2021","unstructured":"Thulin MH, M\u00e4\u00e4tt\u00e4 J, Linder A, Sterbova S, Ohlsson C, Damber J-E et al (2021) Inhibition of STAT3 prevents bone metastatic progression of prostate cancer in vivo. Prostate 81(8):452\u2013462","journal-title":"Prostate"},{"issue":"20","key":"12948_CR64","doi-asserted-by":"publisher","first-page":"4619","DOI":"10.1158\/1078-0432.CCR-15-0242","volume":"21","author":"D Cui","year":"2015","unstructured":"Cui D, Dai J, Keller JM, Mizokami A, Xia S, Keller ET (2015) Notch Pathway Inhibition Using PF-03084014, a \u03b3-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer. Clin Cancer Res 21(20):4619\u20134629","journal-title":"Clin Cancer Res"},{"issue":"19","key":"12948_CR65","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1200\/JCO.2011.36.8282","volume":"30","author":"AW Tolcher","year":"2012","unstructured":"Tolcher AW, Messersmith WA, Mikulski SM, Papadopoulos KP, Kwak EL, Gibbon DG et al (2012) Phase I Study of RO4929097, a Gamma Secretase Inhibitor of Notch Signaling, in Patients With Refractory Metastatic or Locally Advanced Solid Tumors. J Clin Oncol 30(19):2348\u20132353","journal-title":"J Clin Oncol"},{"issue":"5","key":"12948_CR66","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1158\/1535-7163.MCT-20-0228","volume":"20","author":"KT Schmidt","year":"2021","unstructured":"Schmidt KT, Chau CH, Strope JD, Huitema ADR, Sissung TM, Price DK et al (2021) Antitumor Activity of NLG207 (Formerly CRLX101) in Combination with Enzalutamide in Preclinical Prostate Cancer Models. Mol Cancer Ther 20(5):915\u2013924","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"12948_CR67","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1093\/oncolo\/oyac100","volume":"27","author":"KT Schmidt","year":"2022","unstructured":"Schmidt KT, Karzai F, Bilusic M, Cordes LM, Chau CH, Peer CJ et al (2022) A Single-arm Phase II Study Combining NLG207, a Nanoparticle Camptothecin, with Enzalutamide in Advanced Metastatic Castration-resistant Prostate Cancer Post-Enzalutamide. Oncologist 27(9):718\u2013e694","journal-title":"Oncologist"},{"issue":"22","key":"12948_CR68","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2016.66.9697","volume":"34","author":"C Sternberg","year":"2016","unstructured":"Sternberg C, Armstrong A, Pili R, Ng S, Huddart R, Agarwal N et al (2016) Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol 34(22):2636\u20132643","journal-title":"J Clin Oncol"},{"issue":"70","key":"12948_CR69","doi-asserted-by":"publisher","first-page":"115054","DOI":"10.18632\/oncotarget.23014","volume":"8","author":"N Jiang","year":"2017","unstructured":"Jiang N, Ke B, Hjort-Jensen K, Iglesias-Gato D, Wang Z, Chang P et al (2017) YAP1 regulates prostate cancer stem cell-like characteristics to promote castration resistant growth. Oncotarget 8(70):115054\u2013115067","journal-title":"Oncotarget"},{"issue":"6","key":"12948_CR70","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1002\/cam4.675","volume":"5","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Jin Z, Zhou H, Ou X, Xu Y, Li H et al (2016) Suppression of prostate cancer progression by cancer cell stemness inhibitor napabucasin. Cancer Med 5(6):1251\u20131258","journal-title":"Cancer Med"},{"issue":"3","key":"12948_CR71","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.bbrc.2014.08.154","volume":"452","author":"J Zhang","year":"2014","unstructured":"Zhang J, Shen C, Wang L, Ma Q, Xia P, Qi M et al (2014) Metformin inhibits epithelial\u2013mesenchymal transition in prostate cancer cells: Involvement of the tumor suppressor miR30a and its target gene SOX4. Biochem Biophys Res Commun 452(3):746\u2013752","journal-title":"Biochem Biophys Res Commun"},{"issue":"8","key":"12948_CR72","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/S1470-2045(25)00231-1","volume":"26","author":"S Gillessen","year":"2025","unstructured":"Gillessen S, Murphy L, James ND, Sachdeva A, El-Taji O, Abdel-Aty H et al (2025) Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol. Lancet Oncol 26(8):1018\u20131030","journal-title":"Lancet Oncol"},{"issue":"4","key":"12948_CR73","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.cell.2018.01.009","volume":"172","author":"S Su","year":"2018","unstructured":"Su S, Chen J, Yao H, Liu J, Yu S, Lao L et al (2018) CD10\u2009+\u2009GPR77+ Cancer-Associated Fibroblasts Promote Cancer Formation and Chemoresistance by Sustaining Cancer Stemness. Cell 172(4):841\u201356e16","journal-title":"Cell"},{"key":"12948_CR74","doi-asserted-by":"crossref","unstructured":"Xiong Z, Yu S-L, Xie Z-X, Zhuang R-L, Peng S-R, Wang Q et al (2024) Cancer-associated fibroblasts promote enzalutamide resistance and PD-L1 expression in prostate cancer through CCL5-CCR5 paracrine axis. iScience 27(5)","DOI":"10.1016\/j.isci.2024.109674"},{"key":"12948_CR75","doi-asserted-by":"crossref","unstructured":"Pan J, Ma Z, Liu B, Qian H, Shao X, Liu J et al (2023) Identification of cancer-associated fibroblasts subtypes in prostate cancer. Front Immunol. Volume 14\u20132023","DOI":"10.3389\/fimmu.2023.1133160"},{"issue":"2","key":"12948_CR76","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/nm.2284","volume":"17","author":"C Liu","year":"2011","unstructured":"Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H et al (2011) The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 17(2):211\u2013215","journal-title":"Nat Med"},{"issue":"14","key":"12948_CR77","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1158\/0008-5472.CAN-12-0540","volume":"72","author":"S Saini","year":"2012","unstructured":"Saini S, Majid S, Shahryari V, Arora S, Yamamura S, Chang I et al (2012) miRNA-708 Control of CD44\u2009+\u2009Prostate Cancer\u2013Initiating Cells. Cancer Res 72(14):3618\u20133630","journal-title":"Cancer Res"},{"key":"12948_CR78","doi-asserted-by":"publisher","first-page":"e43511","DOI":"10.7554\/eLife.43511","volume":"8","author":"X Yan","year":"2019","unstructured":"Yan X, Tang B, Chen B, Shan Y, Yang H, Reproducibility P (2019) Cancer B. Replication Study: The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. eLife 8:e43511","journal-title":"eLife"},{"issue":"3","key":"12948_CR79","doi-asserted-by":"publisher","first-page":"e33729","DOI":"10.1371\/journal.pone.0033729","volume":"7","author":"D Kong","year":"2012","unstructured":"Kong D, Heath E, Chen W, Cher ML, Powell I, Heilbrun L et al (2012) Loss of Let-7 Up-Regulates EZH2 in Prostate Cancer Consistent with the Acquisition of Cancer Stem Cell Signatures That Are Attenuated by BR-DIM. PLoS ONE 7(3):e33729","journal-title":"PLoS ONE"},{"issue":"1","key":"12948_CR80","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12885-018-5228-2","volume":"19","author":"X Qiu","year":"2019","unstructured":"Qiu X, Wang W, Li B, Cheng B, Lin K, Bai J et al (2019) Targeting Ezh2 could overcome docetaxel resistance in prostate cancer cells. BMC Cancer 19(1):27","journal-title":"BMC Cancer"},{"key":"12948_CR81","doi-asserted-by":"publisher","first-page":"208e11","DOI":"10.1016\/j.urology.2017.01.001","volume":"105","author":"J-z Liu","year":"2017","unstructured":"Liu J-z, Yin F-y, Yan C-y, Wang H, Luo X-h (2017) Regulation of Docetaxel Sensitivity in Prostate Cancer Cells by hsa-miR-125a-3p via Modulation of Metastasis-Associated Protein 1 Signaling. Urology 105:208e11\u2013e17","journal-title":"Urology"},{"issue":"3","key":"12948_CR82","doi-asserted-by":"publisher","first-page":"963","DOI":"10.3892\/or.2021.7925","volume":"45","author":"J Zhu","year":"2021","unstructured":"Zhu J, Qin P, Cao C, Dai G, Xu L, Yang D (2021) Use of miR\u2013145 and testicular nuclear receptor 4 inhibition to reduce chemoresistance to docetaxel in prostate cancer. Oncol Rep 45(3):963\u2013974","journal-title":"Oncol Rep"},{"issue":"1","key":"12948_CR83","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/1471-2407-13-61","volume":"13","author":"X Fan","year":"2013","unstructured":"Fan X, Chen X, Deng W, Zhong G, Cai Q, Lin T (2013) Up-regulated microRNA-143 in cancer stem cells differentiation promotes prostate cancer cells metastasis by modulating FNDC3B expression. BMC Cancer 13(1):61","journal-title":"BMC Cancer"},{"issue":"30","key":"12948_CR84","doi-asserted-by":"publisher","first-page":"29161","DOI":"10.18632\/oncotarget.4971","volume":"6","author":"S Gaur","year":"2015","unstructured":"Gaur S, Wen Y, Song JH, Parikh NU, Mangala LS, Blessing AM et al (2015) Chitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagy. Oncotarget 6(30):29161\u201329177","journal-title":"Oncotarget"},{"issue":"4","key":"12948_CR85","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.3390\/ijms25042123","volume":"25","author":"W Li","year":"2024","unstructured":"Li W, Wang Y, Liu X, Wu S, Wang M, Turowski SG et al (2024) Developing Folate-Conjugated miR-34a Therapeutic for Prostate Cancer: Challenges and Promises. Int J Mol Sci 25(4):2123","journal-title":"Int J Mol Sci"},{"issue":"11","key":"12948_CR86","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1038\/s41416-020-0802-1","volume":"122","author":"DS Hong","year":"2020","unstructured":"Hong DS, Kang Y-K, Borad M, Sachdev J, Ejadi S, Lim HY et al (2020) Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. Br J Cancer 122(11):1630\u20131637","journal-title":"Br J Cancer"},{"issue":"7","key":"12948_CR87","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","volume":"15","author":"ED Kwon","year":"2014","unstructured":"Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJM et al (2014) Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 15(7):700\u2013712","journal-title":"Lancet Oncol"},{"issue":"5","key":"12948_CR88","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1200\/JCO.19.01638","volume":"38","author":"ES Antonarakis","year":"2020","unstructured":"Antonarakis ES, Piulats JM, Gross-Goupil M, Goh J, Ojamaa K, Hoimes CJ et al (2020) Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study. J Clin Oncol 38(5):395\u2013405","journal-title":"J Clin Oncol"},{"issue":"4","key":"12948_CR89","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/j.euo.2025.04.016","volume":"8","author":"S van Wilpe","year":"2025","unstructured":"van Wilpe S, Taha T, Rothmann EC, Altshuler E, Park J, Ledet EM et al (2025) Efficacy of Anti-PD-(L)1 Immunotherapy in Patients with DNA Mismatch Repair\u2013deficient Metastatic Castration-resistant Prostate Cancer. Eur Urol Oncol 8(4):1020\u20131029","journal-title":"Eur Urol Oncol"},{"issue":"22","key":"12948_CR90","doi-asserted-by":"publisher","first-page":"3839","DOI":"10.1200\/JCO.23.00233","volume":"41","author":"ES Antonarakis","year":"2023","unstructured":"Antonarakis ES, Park SH, Goh JC, Shin SJ, Lee JL, Mehra N et al (2023) Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial. J Clin Oncol 41(22):3839\u20133850","journal-title":"J Clin Oncol"},{"issue":"1","key":"12948_CR91","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3390\/cancers4010193","volume":"4","author":"A Kiessling","year":"2012","unstructured":"Kiessling A, Wehner R, F\u00fcssel S, Bachmann M, Wirth MP, Schmitz M (2012) Tumor-associated antigens for specific immunotherapy of prostate cancer. Cancers (Basel) 4(1):193\u2013217","journal-title":"Cancers (Basel)"},{"issue":"5","key":"12948_CR92","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363(5):411\u2013422","journal-title":"N Engl J Med"},{"issue":"13","key":"12948_CR93","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1200\/JCO.18.02031","volume":"37","author":"JL Gulley","year":"2019","unstructured":"Gulley JL, Borre M, Vogelzang NJ, Ng S, Agarwal N, Parker CC et al (2019) Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol 37(13):1051\u20131061","journal-title":"J Clin Oncol"},{"issue":"1","key":"12948_CR94","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3892\/or.2020.7847","volume":"45","author":"M Noguchi","year":"2021","unstructured":"Noguchi M, Fujimoto K, Arai G, Uemura H, Hashine K, Matsumoto H et al (2021) A randomized phase III trial of personalized peptide vaccination for castration\u2013resistant prostate cancer progressing after docetaxel. Oncol Rep 45(1):159\u2013168","journal-title":"Oncol Rep"},{"issue":"12","key":"12948_CR95","doi-asserted-by":"publisher","first-page":"e008067","DOI":"10.1136\/jitc-2023-008067","volume":"11","author":"DG McNeel","year":"2023","unstructured":"McNeel DG, Emamekhoo H, Eickhoff JC, Kyriakopoulos CE, Wargowski E, Tonelli TP et al (2023) Phase 2 trial of a DNA vaccine (pTVG-HP) and nivolumab in patients with castration-sensitive non-metastatic (M0) prostate cancer. J Immunother Cancer 11(12):e008067","journal-title":"J Immunother Cancer"},{"issue":"4","key":"12948_CR96","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","volume":"28","author":"V Narayan","year":"2022","unstructured":"Narayan V, Barber-Rotenberg JS, Jung I-Y, Lacey SF, Rech AJ, Davis MM et al (2022) PSMA-targeting TGF\u03b2-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat Med 28(4):724\u2013734","journal-title":"Nat Med"},{"issue":"6","key":"12948_CR97","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/s41591-024-02979-8","volume":"30","author":"TB Dorff","year":"2024","unstructured":"Dorff TB, Blanchard MS, Adkins LN, Luebbert L, Leggett N, Shishido SN et al (2024) PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat Med 30(6):1636\u20131644","journal-title":"Nat Med"},{"issue":"3","key":"12948_CR98","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1158\/1535-7163.MCT-20-0446","volume":"20","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, He L, Sadagopan A, Ma T, Dotti G, Wang Y et al (2021) Targeting Radiation-Resistant Prostate Cancer Stem Cells by B7-H3 CAR T Cells. Mol Cancer Ther 20(3):577\u2013588","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"12948_CR99","doi-asserted-by":"publisher","first-page":"e1672494","DOI":"10.1080\/2162402X.2019.1672494","volume":"8","author":"S Yunger","year":"2019","unstructured":"Yunger S, Bar El A, Zeltzer LA, Fridman E, Raviv G, Laufer M et al (2019) Tumor-infiltrating lymphocytes from human prostate tumors reveal anti-tumor reactivity and potential for adoptive cell therapy. Oncoimmunology 8(12):e1672494","journal-title":"Oncoimmunology"},{"issue":"1","key":"12948_CR100","doi-asserted-by":"publisher","first-page":"e005847","DOI":"10.1136\/jitc-2022-005847","volume":"11","author":"J Karbach","year":"2023","unstructured":"Karbach J, Kiselicki D, Brand K, Wahle C, Sinelnikov E, Gustavus D et al (2023) Tumor-infiltrating lymphocytes mediate complete and durable remission in a patient with NY-ESO-1 expressing prostate cancer. J Immunother Cancer 11(1):e005847","journal-title":"J Immunother Cancer"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12948-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12948-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12948-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T12:02:19Z","timestamp":1792584139000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12948-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,21]]},"references-count":100,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12948"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12948-8","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,21]]},"assertion":[{"value":"17 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Clinical Trial Registration","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1770"}}